CD19 and non-Hodgkin lymphoma: An immunotoxin (Anti-B4-bR) targeting CD19 was used against relapsed B-cell non-Hodgkin’s lymphoma (NHL) [30] and the CD19 and CD3 binding bispecific T-cell engager (Blinatumomab) was used to eliminate refractory B-precursor acute lymphoblastic leukemia [31].